Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BriaCell Therapeutics ( (TSE:BCT) ) has issued an update.
BriaCell Therapeutics announced a significant milestone in its Bria-OTS metastatic breast cancer study, where a patient achieved a complete resolution of lung metastasis after treatment with Bria-OTS monotherapy. The patient, who had previously experienced multiple treatment failures, showed no treatment-limited toxicities and maintained stable disease elsewhere. This development highlights the potential of Bria-OTS as a promising therapeutic option, with plans to further explore its efficacy in combination with checkpoint inhibitors to improve outcomes for advanced breast cancer patients.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company is currently working on personalized off-the-shelf immunotherapies, such as Bria-OTS, targeting metastatic breast cancer and other challenging cancer types.
Average Trading Volume: 17,820
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$26.77M
Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.